D-Mannuronsaeure | 577-46-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: D-Mannuronsaeure
• 英文别名: D-Mannuronic Acid；(2S,3S,4S,5S)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid
• CAS: 577-46-8
• 化学式: C₆H₁₀O₇
• 分子量: 194.141
• InChiKey: AEMOLEFTQBMNLQ-VANFPWTGSA-N

物化性质

• 沸点：
  553.4±50.0 °C(Predicted)
• 密度：
  1.748±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  127
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  D-Mannuronsaeure 在 recombinant Arabidopsis thaliana glucuronokinase; molecular weight around 42 kDa 、 5’-三磷酸腺苷 、 magnesium chloride 作用下， 以 aq. buffer 为溶剂， 以95%的产率得到α-D-mannopyranuronic acid 1-phosphate
  参考文献：
  名称：

  Improved one-pot multienzyme (OPME) systems for synthesizing UDP-uronic acids and glucuronides

  摘要：

  高效的一锅多酶（OPME）系统已经建立起来，用于从简单单糖合成UDP-GlcA、UDP-GalA和葡萄糖醛酸酯。

  DOI：

  10.1039/c4cc10306h
• 作为产物：
  描述：

  (2S,3S,4S,5S,6S)-3,4,5-三羟基-6-甲氧基四氢-2H-吡喃-2-羧酸 在 水 、 sodium hydroxide 作用下， 以 水 为溶剂， 反应 16.0h， 以65%的产率得到D-Mannuronsaeure
  参考文献：
  名称：

  Improved one-pot multienzyme (OPME) systems for synthesizing UDP-uronic acids and glucuronides

  摘要：

  高效的一锅多酶（OPME）系统已经建立起来，用于从简单单糖合成UDP-GlcA、UDP-GalA和葡萄糖醛酸酯。

  DOI：

  10.1039/c4cc10306h

文献信息

• [EN] N-SUBSTITUTED MANNOSAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE<br/>[FR] DÉRIVÉS N-SUBSTITUÉS DE MANNOSAMINE, PROCÉDÉ POUR LEUR PRÉPARATION ET LEUR UTILISATION
  申请人：GLYCOM AS

  公开号：WO2012140576A1

  公开（公告）日：2012-10-18

  A compound of the formula (I) wherein R1 is a group removable by hydrogenolysis,and wherein R2 is OH or R2 is -NHR3 wherein R3 is a group removable by hydrogenolysis. The compound can be made from fructose by a Heyns-rearrangement. The compound can be used then to make - free D-mannosamine or its salts, - D-mannosamine building blocks and mannosamine containing oligo- or polysaccharides, - N-acetyl-D-mannosamine and its hydrates and solvates, - neuraminic acid derivatives and, - viral neuraminidase inhibitors.

  公式(I)的化合物，其中R1是可通过氢解去除的基团，且其中R2是OH或R2是-NHR3，其中R3是可通过氢解去除的基团。该化合物可以通过Heyns重排从果糖制备。然后，该化合物可用于制备无游离α-D-甘露糖胺或其盐，α-D-甘露糖胺构建块和含甘露糖胺的寡糖或多糖，N-乙酰-D-甘露糖胺及其水合物和溶剂化物，神经氨酸衍生物以及病毒神经氨酸酶抑制剂。
• Prodrugs activated by targeted catalytic proteins
  申请人：Kenten Henry John

  公开号：US20050123533A1

  公开（公告）日：2005-06-09

  Disclosed and claimed are prodrugs activated by catalytic proteins, such as enzymes and catalytic antibodies. The invention comprehends such prodrugs, as well as haptens, to elicit catalytic antibodies to activate the prodrugs. The prodrugs are useful as cytotoxic chemotherapeutic agents; e.g., as antitumor agents.

  本发明揭示和声明了通过催化蛋白质（如酶和催化抗体）激活的前药。该发明涵盖了这样的前药，以及半抗原，以引发催化抗体以激活前药。这些前药可用作细胞毒性化疗剂，例如，作为抗肿瘤剂。
• Mannich Base N-Oxide Drugs
  申请人：Keana John F.W.

  公开号：US20100016252A1

  公开（公告）日：2010-01-21

  Disclosed are Mannich base N-oxides of drugs containing acidic N—H groups. Pharmaceutical compositions comprising a therapeutically effective amount of Mannich base N-oxides, or a N-oxide rearrangement product, pharmaceutically acceptable salt or prodrug thereof, are also disclosed. Further, disclosed are methods of using the compounds, alone or in combination with one or more other active agents or treatments.

  本发明涉及含有酸性N-H基团的药物的Mannich碱N-氧化物。还公开了包含治疗有效量的Mannich碱N-氧化物、氧化物重排产物、药学上可接受的盐或前药的制药组合物。此外，还公开了使用该化合物的方法，单独或与一种或多种其他活性剂或治疗方法结合使用。
• N-SUBSTITUTED MANNOSAMINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
  申请人：Vrasidas Ioannis

  公开号：US20140046051A1

  公开（公告）日：2014-02-13

  A compound of the formula (1) wherein R 1 is a group removable by hydrogenolysis, and wherein R 2 is OH or R 2 is —NHR 3 wherein R 3 is a group removable by hydrogenolysis. The compound can be made from fructose by a Heyns-rearrangement. The compound can be used then to make free D-mannosamine or its salts, D-mannosamine building blocks and mannosamine containing oligo- or polysaccharides, N-acetyl-D-mannosamine and its hydrates and solvates, neuraminic acid derivatives, and viral neuraminidase inhibitors.

  化合物的公式为（1），其中R1是可通过氢解去除的基团，R2为OH或R2为—NHR3，其中R3是可通过氢解去除的基团。该化合物可由果糖经Heyns重排制备而成。然后，该化合物可用于制备游离D-甘氨酰胺或其盐，D-甘氨酰胺构建块和含有甘氨酰胺的寡糖或多糖，N-乙酰-D-甘氨酰胺及其水合物和溶剂化物，神经酰胺酸衍生物和病毒神经氨酸酶抑制剂。
• Microencapsulation for controlled oral drug delivery system
  申请人：KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY

  公开号：EP0480729A1

  公开（公告）日：1992-04-15

  The present invention provides a microencapsulation method of an oil droplet containing drugs for oral administration using polysaccharide which has metal-chelating capacity and the biocompatible and water-soluble polymer as a capsule material. The drug carrier system obtained in this invention using the microencapsulated emulsion represses the drug release from the system and protects the emulsion and drug from the strong acidic condition of gastric juice. The oil droplet and drug dispersed in the oil droplet was released rapidly in the small intestine with the disintegration of capsule material. The system obtained in this invention can reduce the gastric upset or damages on the stomach and protect drugs from the degradation in the gastric juice. At the same time, the degradation of drug caused by the hepatic first-pass metabolism can be lessened because the drug dispersed in oil droplet can be absorbed via lymphatic absorption.

  本发明提供了一种以具有金属螯合能力的多糖和生物相容性好的水溶性聚合物为胶囊材料，对含有药物的油滴进行微胶囊化的口服方法。本发明利用微胶囊乳剂获得的药物载体系统可抑制药物从系统中释放，并保护乳剂和药物不受胃液强酸性条件的影响。随着胶囊材料的崩解，分散在油滴中的油滴和药物在小肠中迅速释放。本发明得到的系统可以减少胃部不适或对胃的损害，保护药物不被胃液降解。同时，由于分散在油滴中的药物可以通过淋巴吸收，因此可以减少肝脏首过代谢引起的药物降解。